Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methoxetamine (MXE) is a dissociative anesthetic and a derivative of arylcyclohexylamine, structurally related to ketamine and 3-MeO-PCP. It primarily functions as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor and also exhibits activity as a serotonin reuptake inhibitor. Originally synthesized as a research chemical or designer drug, it gained popularity in the early 2010s as a recreational substance due to its hallucinogenic and dissociative effects. Unlike ketamine, methoxetamine was designed to have a longer duration of action and was hypothesized to have lower urotoxicity, though this has not been clinically proven. It is not approved for any medical use and is classified as a controlled substance in numerous countries. Note: In certain clinical contexts, particularly in translations from Chinese regarding respiratory treatments, the name methoxetamine may appear as an erroneous translation for the bronchodilator methoxyphenamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methoxetamine.